Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

• Status: Recruiting
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The effects and safety of caspofungin and corticosteroids is not certain in this population. All Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28 day mortality, the second outcome are time of respiratory rate decreases to less than 25 breath per minute, body temperature lower than 37.3℃.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Chao Yang Hospital
• Treatments: Caspofungin; Echinocandins; Methylprednisolone; Sulfanilamide; Sulfanilamides

Criteria

Inclusion Criteria:

• Immunocompromised Non-HIV Infected Patients

• Partial arterial O2 pressure(PaO2)/FiO2≤300mmHg

• Diagnosed as Pneumocystis Pneumonia

Exclusion Criteria:

• younger than 16 years old

• severe organ failure

• allergic to sulfanilamide, caspofungin or corticosteroid